BMC Infectious Diseases
Volume 18, Issue 1, 2018

Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: A focus on migrants from anti-HCV endemic countries (Article) (Open Access)

Falla A.M.* , Ahmad A.A. , Duffell E. , Noori T. , Veldhuijzen I.K.
  • a University Medical Center Rotterdam, Department of Public Health, Erasmus MC, Rotterdam, Netherlands, Division of Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond, PO Box 70032, Rotterdam, LP, 3000, Netherlands
  • b Hamburg University of Applied Sciences, Faculty Life Sciences / Public Health Research, Department of Health Sciences, Ulmenliet 20, Hamburg, 21033, Germany, University Medical Center Hamburg-Eppendorf, Department of Internal Medicine, Martinistr 52, Hamburg, 20246, Germany
  • c European Centre for Disease Prevention and Control, Granits väg 8, Solna, 171 65, Sweden
  • d European Centre for Disease Prevention and Control, Granits väg 8, Solna, 171 65, Sweden
  • e Division of Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond, PO Box 70032, Rotterdam, LP, 3000, Netherlands, Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Sweden

Abstract

Background: Increasing the proportion diagnosed with and on treatment for chronic hepatitis C (CHC) is key to the elimination of hepatitis C in Europe. This study contributes to secondary prevention planning in the European Union/European Economic Area (EU/EEA) by estimating the number of CHC (anti-HCV positive and viraemic) cases among migrants living in the EU/EEA and born in endemic countries, defining the most affected migrant populations, and assessing whether country of birth prevalence is a reliable proxy for migrant prevalence. Methods: Migrant country of birth and population size extracted from statistical databases and anti-HCV prevalence in countries of birth and in EU/EEA countries derived from a systematic literature search were used to estimate caseload among and most affected migrants. Reliability of country of birth prevalence as a proxy for migrant prevalence was assessed via a systematic literature search. Results: Approximately 11% of the EU/EEA adult population is foreign-born, 79% of whom were born in endemic (anti-HCV prevalence ≥1%) countries. Anti-HCV/CHC prevalence in migrants from endemic countries residing in the EU/EEA is estimated at 2.3%/1.6%, corresponding to ~580,000 CHC infections or 14% of the CHC disease burden in the EU/EEA. The highest number of cases is found among migrants from Romania and Russia (50-60,000 cases each) and migrants from Italy, Morocco, Pakistan, Poland and Ukraine (25-35,000 cases each). Ten studies reporting prevalence in migrants in Europe were identified; in seven of these estimates, prevalence was comparable with the country of birth prevalence and in three estimates it was lower. Discussion: Migrants are disproportionately affected by CHC, account for a considerable number of CHC infections in EU/EEA countries, and are an important population for targeted case finding and treatment. Limited data suggest that country of birth prevalence can be used as a proxy for the prevalence in migrants. © 2018 The Author(s).

Author Keywords

Migrants Hepatitis C virus (HCV) Chronic viral hepatitis Europe Epidemiology

Index Keywords

Russia rating scale Romania Pakistan Europe human statistics and numerical data Poland Viremia Hepatitis C virus chronic hepatitis C Hepatitis C, Chronic Ukraine ethnology Humans migrant secondary prevention reliability European Union prevalence Article major clinical study adult migration endemic disease Italy Transients and Migrants systematic review Russian Federation Morocco

Link
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040348595&doi=10.1186%2fs12879-017-2908-5&partnerID=40&md5=6dad60fe7e066687817d955902f4385b

DOI: 10.1186/s12879-017-2908-5
ISSN: 14712334
Cited by: 7
Original Language: English